Shire to Resubmit Dry-Eye Disease Drug to FDA With New Study Data

Shire said its dry-eye disease drug lifitegrast significantly improved patient symptoms in a new study, supporting a re-submission of the medicine to U.S. regulators early next year.
Reuters Health Information

Full Story →